Abstract
Twelve patients with levodopa-induced dyskinesias were treated with continuous subcutaneous apomorphine. A markedly significant reduction in peak dose dyskinesias occurred over a two-year follow-up.
Copyright 2001 Movement Disorder Society
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antiparkinson Agents / adverse effects
-
Antiparkinson Agents / therapeutic use*
-
Apomorphine / administration & dosage
-
Apomorphine / therapeutic use*
-
Dopamine Agonists / administration & dosage
-
Dopamine Agonists / therapeutic use*
-
Drug Administration Schedule
-
Dyskinesia, Drug-Induced / drug therapy*
-
Female
-
Follow-Up Studies
-
Humans
-
Injections, Subcutaneous
-
Levodopa / adverse effects
-
Levodopa / therapeutic use*
-
Male
-
Middle Aged
-
Parkinson Disease / drug therapy*
-
Prospective Studies
-
Treatment Outcome
Substances
-
Antiparkinson Agents
-
Dopamine Agonists
-
Levodopa
-
Apomorphine